First Tracks Biotherapeutics Inc

NASDAQ:TRAX

Biotechnology

Healthcare
$44.50 -4.87%

-$0.89 today

Market cap
$1.87B
Beta
0.00
P/E (TTM)
-6.1
EPS (TTM)
-$2.81
52W Low $14.72High $26.80

Volume 0.75M

Average 0.43M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$179.01M

FY 2025 · Annual

Net Income

-$166.09M

FY 2025 · Annual

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000
Cost of Revenue0152.35M139.61M
Gross Profit0(152.35M)(139.61M)
Gross Margin———
Research & Development97.59M152.35M139.61M
Selling, General & Admin20.87M28.76M39.39M
Operating Expenses118.46M28.76M39.39M
Depreciation & Amortization2.38M2.4M559K
EBITDA(116.09M)(178.7M)(178.45M)
EBITDA Margin———
Operating Income(118.46M)(181.1M)(179.01M)
Operating Margin———
Interest Income12.31M17.38M0
Interest Expense000
Other Income / Expenses12.31M17.4M12.92M
Income Before Tax(106.15M)(163.71M)(166.09M)
Pre-Tax Margin———
Income Tax Expense000
Net Income(106.15M)(163.71M)(166.09M)
Net Margin———
EPS (Basic)(3.05)0.000.00
EPS (Diluted)(3.05)0.000.00
Weighted Avg Shares34.75M00
Weighted Avg Shares (Diluted)34.75M00

TRAX Earnings Waterfall · TTM

NASDAQ:TRAX · Revenue to Net Income

No earnings data available.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 12, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
424B3424B3 filingNov 4, 2026
424B3424B3 filingNov 4, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

How much revenue does TRAX generate?

First Tracks Biotherapeutics Inc (TRAX) reported $0.00 of revenue in fiscal 2025.

Is TRAX profitable?

First Tracks Biotherapeutics Inc (TRAX) reported -$166.09M of net income.